06/04/2026 | Press release | Distributed by Public on 06/04/2026 14:08
|
Delaware
|
87-0494517
|
||||
|
(State or other jurisdiction
|
(I.R.S. Employer
|
||||
|
of incorporation or organization)
|
Identification No.)
|
||||
|
Large accelerated filer
|
[ ]
|
Accelerated filer
|
[X]
|
|||||||||||||||||
|
Non-accelerated filer
|
[ ]
|
Smaller reporting company
|
[ ]
|
|||||||||||||||||
|
Emerging growth company
|
[ ]
|
|||||||||||||||||||
|
Exhibit Number
|
Item
|
Incorporated by Reference herein from Form or Schedule
|
Filing Date
|
SEC File/Registration Number
|
|||||||||||||
|
4.1
|
10-Q (Exhibit 3.1)
|
8/4/2023
|
000-26642
|
||||||||||||||
|
4.2
|
8-K (Exhibit 3.1)
|
10/15/2020
|
000-26642
|
||||||||||||||
|
4.3
|
10-K (Exhibit 4.1)
|
8/15/2011
|
000-26642
|
||||||||||||||
|
5.1*
|
Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
|
||||||||||||||||
|
23.1*
|
Consent of Independent Registered Public Accounting Firm.
|
||||||||||||||||
|
23.2*
|
Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (contained in Exhibit 5.1 hereto).
|
||||||||||||||||
|
24.1*
|
Power of Attorney (included in the signature page of this registration statement).
|
||||||||||||||||
|
99.1*
|
Myriad Genetics, Inc. Amended and Restated 2012 Employee Stock Purchase Plan.
|
|
|||||||||||||||
|
107*
|
Filing Fee Table.
|
||||||||||||||||
|
MYRIAD GENETICS, INC.
|
|||||
|
By
|
/s/ Samraat S. Raha
|
||||
|
Samraat S. Raha
|
|||||
|
President, Chief Executive Officer and Director
|
|||||
|
Signature
|
Title
|
Date
|
||||||||||||
|
/s/ Samraat S. Raha
|
President, Chief Executive Officer and Director (Principal Executive Officer)
|
June 4, 2026
|
||||||||||||
|
Samraat S. Raha
|
||||||||||||||
|
/s/ Benjamin R. Wheeler
|
Chief Financial Officer (Principal Financial and Accounting Officer)
|
June 4, 2026
|
||||||||||||
|
Benjamin R. Wheeler
|
||||||||||||||
|
/s/ S. Louise Phanstiel
|
Chair of the Board
|
June 4, 2026
|
||||||||||||
|
S. Louise Phanstiel
|
||||||||||||||
|
/s/ Paul M. Bisaro
|
Director
|
June 4, 2026
|
||||||||||||
|
Paul M. Bisaro
|
||||||||||||||
|
/s/ Mark S. Davis
|
Director
|
June 4, 2026
|
||||||||||||
|
Mark S. Davis
|
||||||||||||||
|
/s/ Heiner Dreismann
|
Director
|
June 4, 2026
|
||||||||||||
|
Heiner Dreismann Ph.D.
|
||||||||||||||
|
/s/ Rashmi Kumar
|
Director
|
June 4, 2026
|
||||||||||||
|
Rashmi Kumar
|
||||||||||||||
|
/s/ Lee N. Newcomer
|
Director
|
June 4, 2026
|
||||||||||||
|
Lee N. Newcomer, M.D.
|
||||||||||||||
|
/s/ Colleen F. Reitan
|
Director
|
June 4, 2026
|
||||||||||||
|
Colleen F. Reitan
|
||||||||||||||
|
/s/ Daniel M. Skovronsky
|
Director
|
June 4, 2026
|
||||||||||||
|
Daniel M. Skovronsky, M.D., Ph.D.
|
||||||||||||||